Clinical Trial

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2026-12 2026-07-24
minor Completion pushed: 2026-06 -> 2027-12 2026-07-24
Trial Details
NCT Number NCT06437509
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 66 participants
Start Date 2024-06-13
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23